Railway Pension Investments Ltd Purchases 40,300 Shares of Bristol Myers Squibb Company $BMY

Railway Pension Investments Ltd grew its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY) by 3.7% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,139,600 shares of the biopharmaceutical company’s stock after acquiring an additional 40,300 shares during the quarter. Railway Pension Investments Ltd owned 0.06% of Bristol Myers Squibb worth $51,396,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in BMY. Earned Wealth Advisors LLC raised its holdings in Bristol Myers Squibb by 35.1% in the 3rd quarter. Earned Wealth Advisors LLC now owns 6,231 shares of the biopharmaceutical company’s stock valued at $281,000 after buying an additional 1,618 shares during the last quarter. Gateway Investment Advisers LLC grew its holdings in Bristol Myers Squibb by 10.0% during the 3rd quarter. Gateway Investment Advisers LLC now owns 113,457 shares of the biopharmaceutical company’s stock worth $5,117,000 after acquiring an additional 10,284 shares during the period. Fifth Third Wealth Advisors LLC raised its position in shares of Bristol Myers Squibb by 10.2% in the 3rd quarter. Fifth Third Wealth Advisors LLC now owns 46,987 shares of the biopharmaceutical company’s stock worth $2,119,000 after acquiring an additional 4,361 shares in the last quarter. Capital Advisors Inc. OK lifted its stake in shares of Bristol Myers Squibb by 42.0% in the 3rd quarter. Capital Advisors Inc. OK now owns 17,891 shares of the biopharmaceutical company’s stock valued at $807,000 after purchasing an additional 5,293 shares during the period. Finally, Davidson Investment Advisors grew its stake in Bristol Myers Squibb by 4.3% during the third quarter. Davidson Investment Advisors now owns 303,353 shares of the biopharmaceutical company’s stock worth $13,681,000 after purchasing an additional 12,492 shares during the period. 76.41% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the stock. Citigroup reduced their price objective on shares of Bristol Myers Squibb from $48.00 to $45.00 and set a “neutral” rating for the company in a research report on Monday, November 17th. HSBC reissued a “hold” rating and issued a $53.00 price target on shares of Bristol Myers Squibb in a research report on Wednesday, December 10th. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of Bristol Myers Squibb in a report on Monday, November 3rd. Dbs Bank raised Bristol Myers Squibb to a “moderate buy” rating in a research report on Thursday, October 2nd. Finally, Truist Financial set a $65.00 target price on Bristol Myers Squibb in a research report on Wednesday, December 3rd. Six equities research analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $54.62.

Bristol Myers Squibb Trading Down 0.9%

Shares of BMY opened at $53.46 on Monday. The firm has a market cap of $108.82 billion, a P/E ratio of 18.06, a price-to-earnings-growth ratio of 8.89 and a beta of 0.29. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $63.33. The company has a debt-to-equity ratio of 2.39, a quick ratio of 1.17 and a current ratio of 1.27. The business has a 50-day moving average of $49.82 and a 200 day moving average of $47.52.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $1.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.52 by $0.11. Bristol Myers Squibb had a net margin of 12.57% and a return on equity of 76.53%. The company had revenue of $12.22 billion for the quarter, compared to analyst estimates of $11.75 billion. During the same quarter in the previous year, the firm posted $1.80 earnings per share. The company’s quarterly revenue was up 2.8% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. As a group, research analysts forecast that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, February 2nd. Investors of record on Friday, January 2nd will be paid a dividend of $0.63 per share. This is an increase from Bristol Myers Squibb’s previous quarterly dividend of $0.62. This represents a $2.52 annualized dividend and a yield of 4.7%. The ex-dividend date of this dividend is Friday, January 2nd. Bristol Myers Squibb’s dividend payout ratio is presently 85.14%.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.